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Background: Major depressive disorder (MDD) is common
among children and adolescents and is associated with func-
tional impairment and suicide.
Purpose: To update the 2009 U.S. Preventive Services Task
Force (USPSTF) systematic review on screening for and treat-
ment of MDD in children and adolescents in primary care
settings.
Data Sources: Several electronic searches (May 2007 to Febru-
ary 2015) and searches of reference lists of published literature.
Study Selection: Trials and recent systematic reviews of treat-
ment, test–retest studies of screening, and trials and large cohort
studies for harms.
Data Extraction: Data were abstracted by 1 investigator and
checked by another; 2 investigators independently assessed
study quality.
Data Synthesis: Limited evidence from 5 studies showed that
such tools as the Beck Depression Inventory and Patient Health
Questionnaire for Adolescents had reasonable accuracy for
identifying MDD among adolescents in primary care settings. Six
trials evaluated treatment. Several individual fair- and good-
quality studies of fluoxetine, combined fluoxetine and cognitive
behavioral therapy, escitalopram, and collaborative care demon-
strated benefits of treatment among adolescents, with no asso-
ciated harms.
Limitation: The review included only English-language studies,
narrow inclusion criteria focused only on MDD, high thresholds
for quality, potential publication bias, limited data on harms, and
sparse evidence on long-term outcomes of screening and treat-
ment among children younger than 12 years.
Conclusion: No evidence was found of a direct link between
screening children and adolescents for MDD in primary care or
similar settings and depression or other health-related out-
comes. Evidence showed that some screening tools are accurate
and some treatments are beneficial among adolescents (but not
younger children), with no evidence of associated harms.
Primary Funding Source: Agency for Healthcare Research and
Quality.
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Major depressive disorder (MDD) is relatively com-mon in childhood and adolescence and is associ-
ated with functional impairment and suicide. Nationally
representative samples have indicated a past-year
prevalence of approximately 8% for adolescents (1, 2)
and roughly 3% in younger children (aged 8 to 15
years) (3). The prevalence of depression in primary care
settings may be twice that of community samples of
children and adolescents (4) and seems to be increas-
ing (5). In addition, nationally representative studies
have indicated that fewer than one half of children and
adolescents with major depression receive treatment
for mental health issues (2, 3, 6).
Primary care providers can play a critical role in
identifying depression among children and adoles-
cents, particularly because youth with mental health is-
sues frequently use primary care services. Because
primary care providers are often the first point of pro-
fessional contact for children and their families during
times of distress, they can facilitate early identification
of mental health issues; begin initial management; and
refer children, as necessary, for further mental health
assessment and treatment. They also serve vital roles in
collaborative care and practice networks that include
mental health specialists.
Schools are also important in identifying and treat-
ing depression in children and adolescents. In 2011,
12% of adolescents aged 12 to 17 years reported re-
ceiving mental health care at school (2).
Early identification and treatment may be particu-
larly important because of the long-term and recurrent
nature of MDD (7) and its myriad negative sequelae.
Associated functional impairment; decreased aca-
demic performance; and troubled relationships with
parents, siblings, and peers are common and can affect
developmental trajectories (8, 9). In addition, children
and adolescents with depression are likely to have
other comorbid mental health problems (7, 10); so-
matic symptoms, such as headache and migraine,
stomach aches, and musculoskeletal pain; and chronic
medical conditions, such as asthma and diabetes (11).
Childhood and adolescent MDD is associated with in-
creased risk for suicidal thoughts, attempts, and com-
pletions (12).
In 2009, the U.S. Preventive Services Task Force
(USPSTF) guidelines recommended routine screening
for depression in children and adolescents aged 12 to
18 years in primary care settings when resources are
available for additional evaluation and care (13, 14). Al-
though most experts from family medicine, pediatrics,
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nursing, psychology, and child psychiatry endorse rou-
tine surveillance for youth at high risk for depression
(15), routine universal screening is still debated. Some
pediatricians report discomfort with screening for and
diagnosing depression, citing lack of self-efficacy, train-
ing, or experience specific to delivering mental health
care (16). Some providers are also concerned about
access to mental health services for patients with posi-
tive screening results.
The objective of this report is to update the recom-
mendations released in 2009 for screening adolescents
and children for MDD in primary care and similar set-
tings (such as school-based clinics).
METHODS
Scope of the Review
We searched for evidence on the benefits and
harms of screening; accuracy of feasible screening
tests; and potential benefits and risks of treating MDD
using collaborative care, psychotherapy, or selective
serotonin reuptake inhibitors (SSRIs) among children
and adolescents seen in primary care or similar set-
tings, such as school-based clinics. We also wanted to
determine whether the benefits and harms differed by
age, sex, or race/ethnicity. Appendix Tables 1 and 2
and Appendix Figures 1 and 2 (available at www.annals
.org) show key questions; search strings; analytic
framework; and numbers of identified articles,
screened articles, eligible articles for full-text review,
and included articles organized as a PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses) tree (for studies published since May 2007,
the end date for the 2009 review's searches).
Data Sources and Searches
We searched PubMed (MEDLINE), the Cochrane Li-
brary, and PsychInfo for English-language articles pub-
lished from May 2007 to 4 February 2015. Unpublished
literature was identified via searches of ClinicalTrials.
gov, Health Services Research Projects in Progress, and
the World Health Organization's International Clinical
Trials Registry Platform. We also reviewed and in-
cluded, as appropriate, studies from reference lists of
pertinent review articles and all literature suggested by
peer reviewers or public comment respondents. Ap-
pendix Table 1 and the full evidence report (available
at www.uspreventiveservicestaskforce.org) include all
of the search strategies used for each key question and
the databases searched.
Two investigators independently reviewed titles
and abstracts. We dually and independently reviewed
the full text of studies that at least 1 reviewer indicated
as potentially meeting our prespecified criteria for each
key question, according to initial abstract review. To
reduce heterogeneity and ensure focus on children
and adolescents with more serious symptoms because
they are more likely to have severe functional impair-
ment and suicidality, we restricted inclusion of efficacy
and harms studies to those in which at least 50% of
participants had an MDD diagnosis. Screening accu-
racy studies had to be done in primary care or similar
settings, be of feasible length and format to administer
in a setting similar to primary care, and include a com-
parison against a gold-standard assessment tool. We
included randomized and nonrandomized trials pub-
lished between May 2007 and 4 February 2015 and
systematic reviews published between January 2011
and 4 February 2015 of MDD treatment efficacy and
harms, test–retest studies of screening for MDD, and
cohort studies with at least 1000 participants for studies
of screening and treatment harms.
In addition to the new literature searches, we also
applied, dually and independently, the inclusion and
exclusion criteria described previously to all studies
from the 2009 review (17), which included articles pub-
lished from 1990 to May 2007 that focused on screen-
ing for and treatment of depression, but not specifically
MDD, in children and adolescents. The exact differ-
ences between the inclusion and exclusion criteria ap-
plied in the current and former reviews are docu-
mented in the full evidence report at www.uspreventive
servicestaskforce.org.
Data Extraction and Quality Assessment
Using predefined criteria developed by the
USPSTF and others for additional criteria for diagnostic
accuracy studies, 2 investigators independently as-
sessed the quality of each study as good, fair, or poor
(18). We resolved disagreements by discussion and
consensus. For screening accuracy studies, flaws that
resulted in poor-quality ratings included use of an inap-
propriate reference standard, improper administration
of the screening test, biased ascertainment of the ref-
erence standard, very small sample size, or very nar-
rowly selected spectrum of patients. For treatment effi-
cacy and harms studies, flaws that resulted in poor-
quality ratings included high overall attrition (at least
20%) or differential attrition (at least 15%) between
study groups, unreliable or invalid measurement instru-
ments or unequal application across study groups (in-
cluding not masking outcome assessment), and little or
no attention given to key confounders; and, for ran-
domized, controlled trials, the lack of an intention-to-
treat analysis. We excluded all studies dually deter-
mined to be of poor quality. We rated the overall body
of evidence for each key question using the system de-
veloped by the USPSTF (18).
Data Synthesis and Analysis
We organized our findings according to the key
questions. We used Comprehensive Meta Analysis, ver-
sion 3 (Biostat), to calculate effect sizes and 95% CIs.
We planned to use meta-analysis to pool the efficacy
outcomes by drug (such as escitalopram trials) and
drug family (such as all SSRIs), but heterogeneity across
studies limited the number of combinable interventions
and outcomes, which precluded the calculation of
pooled estimates.
Role of the Funding Source
The Agency for Healthcare Research and Quality
funded this study under a contract to support the work
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of the USPSTF. Members of the USPSTF and the
Agency medical officer assisted in the development of
the review's scope, key questions, and analytic frame-
work. The Agency for Healthcare Research and Quality
reviewed and approved this manuscript before publi-
cation, but the authors are solely responsible for its
content and the decision to submit it for publication.
RESULTS
Only 2 new treatment efficacy studies met our cri-
teria (19, 20). The studies included in the 2009 review,
when re-reviewed against our criteria, yielded 5 studies
on screening accuracy (21–24) and 4 trials in 6 publica-
tions on treatment efficacy (3 publications on 1 trial
[25–27] and 1 publication each on the other 3 trials
[28–30]).
Benefits, Yield, and Harms of Screening
We found no trials that directly assessed the bene-
fits or harms of screening children or adolescents for
MDD in primary care settings. We also did not find
studies that addressed whether screening increases the
proportion of children or adolescents identified with
MDD or results in harms.
No meta-analyses or retrospective cohort studies
met our inclusion criteria. We excluded studies if less
than half of the sample of children and adolescents had
MDD or did not report outcomes for those with MDD
separately (31–34). We also excluded studies (35–38)
that evaluated paroxetine as a treatment method be-
cause its use is contraindicated among children and
adolescents due to concern for increased risk for
suicidality.
Accuracy of Screening Instruments
Five fair-quality studies included in the 2009 re-
view, but no studies published since, met our inclusion
and quality criteria (21, 23, 24, 39, 40) (Table 1) for
accuracy of screening instruments. These 5 studies ex-
amined such instruments as the Patient Health Ques-
tionnaire for Adolescents, Beck Depression Inventory
(BDI), Center for Epidemiologic Studies Depression
Scale, and Clinical Interview Schedule–Revised ques-
tionnaire. Four studies were done in schools, and 1 was
done in a primary care setting. No study included chil-
dren younger than 11 years.
In summary, the Patient Health Questionnaire for
Adolescents and BDI reported the highest sensitivity
(range, 73% to 90%) and specificity (range, 81% to
94%) (21, 39, 40). Across all tests and studies, the pos-
itive predictive value was low and variable, ranging
from 8% to 56%. The negative predictive value was
91% for the Clinical Interview Schedule–Revised ques-
tionnaire (24), greater than 99% for both studies of BDI
that used a consistent cutoff score of 11 (21, 39), and
99% for the Center for Epidemiologic Studies Depres-
sion Scale (23, 39). With respect to subgroup differ-
ences, we found inconsistent results for sex differences
in accuracy, with 1 study finding greater sensitivity and
specificity for boys (39) and the other for girls (23).
Benefits and Harms of Treatment
Six trials reported in 8 publications (4 trials re-
ported in 6 publications included in the 2009 review
[25–30] and 2 newer studies [19, 20]) met our inclusion
criteria for benefits and harms of treatment. Interven-
tions were tested, including SSRIs (fluoxetine, escitalo-
pram, and citalopram), cognitive behavioral therapy
Table 1. Accuracy of Screening Tests for Childhood Depression
Study, Year (Reference) USPSTF
Quality
Patients, n Sampling Frame Age, y Instrument
Johnson et al, 2002 (40) Fair 403* English-speaking youth with ≥9 y of education
from primary care and school nurses' offices
in California, Ohio, New Jersey, and New York
Range: 13–18 PHQ-A positive
Canals et al, 2001 (21) Fair 290 All age-eligible children per municipal census
in urban Spain recruited and assessed
through schools
Range: 17–18 BDI score ≥11
BDI score ≥16
Roberts et al, 1991 (39) Fair 1704 Random sample of 9 high schools in 5 communities
(stratified by school) in west-central Oregon;
rural population oversampled to get equal urban
and rural proportions
Mean: 16.6 BDI score ≥11
CES-D score ≥24
Garrison et al, 1991 (23) Fair 332 Students in or transferring to designated schools
for middle or high school in southeastern
metropolitan school district; United States
Range: 11–15 CES-D score ≥22
CES-D score ≥12
Patton et al, 1999 (24) Fair 158 45 schools in Victoria, Australia, selected with
probability proportional to number of students
in year 9 in each of 3 types of schools; 2 classes
randomly selected from each school
Mean: 15.7 CIS-R positive
BDI = Beck Depression Inventory; CES-D = Center for Epidemiological Studies Depression Scale; CIDI = Composite International Diagnostic
Interview; CIS-R = Clinical Interview Schedule–Revised; NR = not reported; PHQ-A = Patient Health Questionnaire for Adolescents;
SCAN = Schedules for Clinical Assessment in Neuropsychiatry; USPSTF = U.S. Preventive Services Task Force.
* A total of 403 patients completed screening and diagnostic interviews, but 162 were excluded because of the time lag between screening and the
interview.
† The clinical validation interview included items from the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, Structured
Clinical Interview; Primary Care Evaluation of Mental Disorders Clinical Evaluation Guide; and Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Global Assessment of Functioning.
‡ CI calculated from reported SEs.
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(CBT), fluoxetine combined with CBT, and collaborative
care. We rated 1 trial included in the 2009 review
(TADS [the Treatment for Adolescents With Depression
Study]) and 3 publications that met inclusion criteria
and reported on different outcomes, as good quality
(25–27). The authors reported benefits and harms of 3
interventions (fluoxetine only, CBT only, and combined
fluoxetine and CBT) compared with placebo among
adolescents aged 12 to 17 years. Two fair-quality,
placebo-controlled trials that studied escitalopram met
inclusion criteria. One was a previously reported trial (in
the 2009 review) done among children and adoles-
cents aged 6 to 17 years (28), and the other was a new
trial done among adolescents aged 12 to 17 years (19).
The fourth trial tested citalopram versus placebo in a
sample of children and adolescents aged 7 to 17 years
(29) and was included in the 2009 review. The fifth trial
included in the prior review focused on testing a CBT
intervention among adolescents aged 14 to 18 years
(30). A sixth recently published trial tested the efficacy
of a collaborative care intervention done in 9 pediatric
and family medicine clinics among adolescents aged
13 to 17 years (20). None of the psychotherapy or com-
bined intervention trials included children younger
than 12 years. In addition, with 1 exception, all trials
lasted 8 to 12 weeks; only the collaborative care trial
examined longer-term outcomes (Table 2).
One good-quality trial (TADS) found significant as-
sociations between fluoxetine and response to treat-
ment (25) (absolute risk difference, 25.7%) and be-
tween the combined fluoxetine and CBT intervention
and response (absolute risk difference, 36.2%). Thus,
evidence from this trial suggests that fluoxetine may be
associated with large effect sizes in the acute phase.
One of the 2 included escitalopram trials demonstrated
efficacy, although the effect sizes for response to treat-
ment were notably smaller than those for the fluoxetine
trial. In addition, this escitalopram trial was the only one
that examined efficacy by age group (but not by sex,
race, or ethnicity) by testing differences in efficacy and
then separately reported outcomes for adolescents
aged 12 to 17 years and children aged 6 to 11 years
(28). Among children, the study found no significant
differences between groups in depression symptoms
or severity. However, among adolescents, all depres-
sion symptom and severity outcomes, except the Chil-
dren's Depression Rating Scale–Revised (CDRS-R)
score, differed significantly by treatment group.
Neither of the 2 psychotherapy trials (both done on
adolescents) published in 4 publications demonstrated
efficacy of CBT (25–27, 30). In contrast, the combined
fluoxetine and CBT group of TADS found significant
differences in response (71.0% vs. 34.8%; P = 0.001;
relative risk, 2.04), including number of depressive
symptoms, remission, global functioning, global bur-
den of psychiatric problems, and quality of life at 12-
week follow-up, compared with the placebo group (25–
27). The collaborative care trial found that intervention
patients had significant decreases in mean CDRS-R
scores at 6 months (8.5) and 12 months (9.4). They
were also more likely to achieve response at both 6
months (odds ratio, 5.2) and 12 months (odds ratio,
3.9) and remission at 12 months (odds ratio, 3.3) than
control patients.
All but 1 efficacy trial provided information on
harms. One good-quality study, TADS (25), found no
significant differences for harm-related adverse events
(AEs) or suicide-related AEs between the fluoxetine,
CBT, or combined fluoxetine and CBT group and the
placebo group. The rate of discontinuation due to AEs,
serious AEs (SAEs), AEs suggestive of self-harm, suicid-
ality, or laboratory values or tests did not differ signifi-
cantly between the escitalopram and placebo groups
in 1 trial (19), other than a greater decrease in platelet
counts in the escitalopram group. The second escitalo-
pram fair-quality trial (28) reported 2 SAEs and 1 poten-
tially suicide-related event in the escitalopram group
and 3 SAEs and 2 potentially suicide-related events in
the placebo group. These differences were not statisti-
cally significant. The fair-quality citalopram trial (29) re-
ported no significant difference between groups in
overall discontinuation (20% in the citalopram group
Table 1—Continued
Sensitivity,% Specificity,% Prevalence,% Positive
Predictive
Value,%
Negative
Predictive
Value,%
Area Under the Curve
(95% CI)
73 94 Assumed current: 9.4† 56 97 NR
90
90
86
96
Current: 3.4 (SE, 1.4; SCAN, seems
to be weighted for selection)
(49)
20
47
99.5
99.6
NR
84 81
75
Weighted data NR 10
8
99.5
99.0
Male: 0.93 (0.84–1.02)‡;
female: 0.83 (0.75–0.91)‡
Male: 0.87 (0.75–0.99)‡;
female: 0.83 (0.75–0.91)‡
18 (male); 83 (female)
85 (male); 84 (female)
83 (male); 77 (female)
49 (male); 38 (female)
Weighted data NR 9 (male); 25 (female)
13 (male); 11 (female)
NR (male and female) Male: 0.61; female: 0.77
18 97 Current: 6.2 (95% CI, 0.3–11.8)
Past 6 mo: 12.1 (95% CI, 5.0–19.3)
(CIDI, estimate weighted for
selection)
49 91 NR
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vs. 21% in the placebo group) or discontinuation due to
AEs (5.9% vs. 5.6%) and no SAEs, including suicidality.
The good-quality collaborative care trial (20) found no
significant differences in the mean number of psychiat-
ric hospitalizations or emergency department visits that
were associated with primary psychiatric diagnoses for
the collaborative care group compared with the control
group (6% vs. 4% and 2% vs. 10%, respectively). Al-
though it is reassuring that none of these studies saw
significant harms, the possibility of harms cannot be de-
finitively excluded because the data were underpow-
ered to show equivalence.
DISCUSSION
Appendix Table 3 (available at www.annals.org)
summarizes the evidence. We found no trials meeting
the inclusion and quality criteria for this review that ex-
amined the overall question of whether routine screen-
ing for pediatric MDD in primary care reduced depres-
sion or improves other health-related outcomes. We
found no new eligible screening studies. The subset of
studies from the 2009 review that continued to meet
inclusion criteria offered limited evidence. Our conclu-
sions are consistent with that of the previous review. In
short, the Patient Health Questionnaire for Adolescents
and BDI continue to outperform other screening tools.
No included studies tested more recent screening tools
that are known to have good psychometric properties.
In addition, some of the older studies included in this
report used adult versions of screening tools that have
since developed child- or adolescent-specific versions
(41, 42). We noted that the positive predictive value of
instruments examined in these studies was relatively
low (range, 10% to 56%); thus, 44% to 90% of persons
with positive screening results for MDD will not, in fact,
have a clinical diagnosis of MDD after further testing.
Moreover, the substantial heterogeneity in interven-
tions, populations, and settings and the lack of replica-
tion studies makes generalization of findings from
these studies challenging. The gap in evidence of ac-
curate MDD screening tools for children persists after
doing this updated review. No included studies exam-
ined harms of screening or whether screening in-
creases the proportion of children or adolescents iden-
tified with MDD.
We identified randomized, controlled trials that
sought to examine the efficacy of collaborative care
and SSRI interventions for children and adolescents
with MDD, although not all showed significant benefit
(specifically, the citalopram trial and 1 escitalopram trial
showed no significant benefit). We found very limited
evidence on psychotherapy. A recent network meta-
analysis on different types of depression in children
and adolescents (major depression, minor depression,
intermittent depression, or dysthymia) found that only
interpersonal therapy was more effective than control
conditions at both short- and long-term follow-up; both
interpersonal therapy and CBT were more effective
than control conditions in the short term. The applica-
bility of these findings to children and adolescents with
screen-detected MDD is unclear (43). Overall, harms of
treatment seemed to be minimal.
Limitations arise from our stringent criteria and
from potential publication bias. In particular, we limited
our review to English-language studies that focused
solely on screening and treatment of MDD in primary
care. We did not address screening or treatment of mi-
nor depression, dysthymia, or depression in subgroups
Table 2. Pooled Estimates of Efficacy Outcomes in Randomized, Controlled Trials Among Children and Adolescents With
MDD
Study, Year (Reference) Pharmacotherapy Patients
Randomly
Assigned, n
Age Range, y Length of
Intervention,wk
Response Rate,%
Treatment Group Placebo Group
March et al, 2004 (25)
Kennard et al, 2006 (26)
Vitiello et al, 2006 (27)
Fluoxetine 221 12 to 17 12 60.6 34.8
Wagner et al, 2004 (29) Citalopram 178 7 to 17 8 47.2 44.7
Wagner et al, 2006 (28) Escitalopram 316 6 to 17 8 63.0 52.0
Emslie et al, 2009 (19) Escitalopram 268 6 to 17 8 64.3 52.9
March et al, 2004 (25)
Kennard et al, 2006 (26)
Vitiello et al, 2006 (27)
CBT 223 12 to 17 12 43.2 34.8
Clarke et al, 1999 (30) CBT 123 14 to 18 8 66.7 48.1
March et al, 2004 (25)
Kennard et al, 2006 (26)
Vitiello et al, 2006 (27)
Fluoxetine and CBT 219 12 to 17 12 71.0 34.8
Richardson et al, 2014 (20) Collaborative care 101 13 to 17 52 A: 48.4 at 6 mo
B: 67.6 at 12 mo
A: 23.4 at 6 mo
B: 38.6 at 12 mo
CBT = cognitive behavioral therapy; CDI-S = Children's Depression Inventory–Short Version; CDRS-R = Children's Depression Rating Scale–Revised;
CGAS = Children's Global Assessment Scale; CGI-I = Clinical Global Impressions–Improvement Scale; MDD = major depressive disorder; NR = not
reported.
* CGI-I score = 1 or 2.
† As measured by a Patient Health Questionnaire-9 score <5 (range, 0–27, with higher scores indicating greater levels of depressive symptoms).
‡ As measured by the Columbia Impairment Scale (range, 0–52, with higher scores indicating greater levels of functional impairment).
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believed to be at high risk (for example, those with pa-
rental depression or comorbid mental or physical
health conditions). Controversy continues about
whether depressive symptoms exist on a continuous
spectrum or whether MDD is a diagnostic entity of dis-
tinct clinical significance, particularly among children
and adolescents (44). Although several studies have
shown that subthreshold depression is a risk factor for
MDD (45), its role in temporal progression to MDD is
not well-understood. Studies done in adults that have
quantified the risk for MDD after having subthreshold
depressive symptoms have shown that approximately
8% are diagnosed with MDD in the following 3 years
(46).
Primary care providers need to be aware of poten-
tial risk factors for MDD and attempt early intervention,
particularly among patients who have already had an
episode of major depression. The burden of universal
screening requires clear evidence of net benefit for
making screening recommendations. Given the paucity
of evidence on the etiologic links among subthreshold
depression, dysthymia, and depression, we chose to
focus on screening for existing MDD rather than pre-
vention. As noted previously, we excluded studies of
paroxetine, which may have resulted in finding little
overall harm from SSRIs.
Our inclusion and exclusion criteria and thresholds
for quality resulted in 5 screening studies comprising
nearly 2900 children and adolescents (none of whom
were younger than 11 years) and 6 treatment trials with
findings published in 8 papers that studied fewer than
1500 children and adolescents with MDD done over
the past 3 decades. As a result, we cannot rule out the
absence of benefits or harms, particularly for rare out-
comes. Guidance suggests that interventions with a rel-
ative risk reduction of 20% to 25% and a control event
rate of 20% require a sample size between 2000 and
4000 (47). Such outcomes as suicidality occur at much
lower rates in the control group and may require even
larger samples to rule out the absence of benefits and
harms.
The difficulty in recruiting and enrolling children
and adolescents into research studies may drive the
methodological limitations of the evidence, such as
small sample size, high attrition, and biased ascertain-
ment of the reference standard in screening studies.
Concerns about risks in this vulnerable population may
limit funding of and enrollment within studies. High at-
trition is common in studies with long-term follow-up
involving children and adolescents, particularly in areas
of mental health. In the context of the dynamic nature
of the health status of children and adolescents, a time
lapse between screening and diagnostic interviews
may result in biased ascertainment of the reference
standard and could explain only moderate sensitivity
and specificity of screening instruments.
Finally, these findings may have limited applicabil-
ity to the typical primary care setting. Included studies
generally drew patients from research or academic set-
tings ranging from 1 to 40 sites. Only 1 screening ac-
curacy study was done in a primary care setting (40);
only 2 treatment trials were done predominantly in clin-
ical settings throughout the community (20, 25). Thus,
few primary care settings were used as the referral
point or the actual intervention setting in our included
studies. In addition, no school clinics served as treat-
ment sites. Included studies had stringent inclusion and
exclusion criteria, such as the exclusion of patients with
several comorbidities. The patients eligible for these
trials may not be representative of all patients with
MDD seen in primary care.
Critical needs for future research include the fol-
lowing:
Populations: Benefits and harms for subgroups de-
fined by age (especially younger than 12 years), sex,
race, ethnicity, or socioeconomic status.
Table 2—Continued
Risk Difference of Response*
(95% CI),%
Mean Change (95% CI)
Depression Severity
(Change in CDRS-R Score)
Depression Symptom
Improvement
(CGI-I Score)
Depression
Symptom Severity
(Change in CDI-S Score)
Global Functioning
(Change in CGAS Score)
25.7 (13.0 to 38.5) −3.1 (−6.7 to 0.6) NR NR 2.4 (0.2 to 4.7)
2.4 (−12.8 to 16.8) NR NR NR NR
10.5 (−1.4 to 22.4) −1.7 (−5.0 to 1.6) −0.2 (−0.5 to 0.1) −0.3 (−0.6 to 0.01) 2.9 (−0.2 to 6.0)
11.4 (0.5 to 22.3) −3.4 (−6.2 to −0.5) −0.3 (−0.6 to −0.1) −0.4 (−0.6 to −0.1) 2.2 (−0.4 to 4.8)
8.4 (−4.4 to 21.2) 1.83 (−2.42 to 6.08) NR NR −0.2 (NR)
18.5 (−3.4 to 40.4) NR NR NR NR
36.2 (23.9 to 48.5) −7.6 (−12.1 to −3.1) NR NR 6.8 (3.5 to 10.2)
A: 26.4 (9.1 to 43.7) at 6 mo†
B: 29.7 (9.6 to 49.8) at 12 mo†
A: −8.5 (−13.4 to −3.6) at 6 mo
B: −9.4 (−15.0 to −3.8) at 12 mo
NR NR A: −4.4 (−8.4 to −0.5) at 6 mo‡
B: −4.3 (−8.3 to −0.3) at 12 mo‡
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Interventions: Benefits and harms from psychother-
apy, non-SSRIs, complementary and alternative medi-
cine, or combination treatments for children with MDD.
Outcomes: Accuracy of screening, whether screen-
ing increases the proportion of children and adoles-
cents identified with depression, patients' uptake of
treatment after screening and referral, harms of screen-
ing, benefits and harms of treatment, and harms of not
treating MDD.
Timing: Long-term outcomes, benefits, and harms
from different frequencies of screening.
Setting: Benefits and harms of screening in differ-
ent locations, including studies sampling from primary
care and school clinic settings.
In conclusion, these studies provide no evidence of
a direct link between screening children and adoles-
cents for MDD in primary care or similar settings and
depression or other health-related outcomes. However,
they do contribute evidence that some screening tools
are accurate and some treatments are beneficial
among adolescents (but not younger children). Al-
though no study found significant harms associated
with treatment, lack of precision hampers our ability to
rule out effects. Evidence gaps sharply limit conclusions
for screening children younger than 12 years; screen-
ing and treatment differences by sex, race, or ethnicity
subgroups; and efficacy of MDD treatment other than
SSRIs.
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Appendix Table 1. Search Strings*
Search Query
1 Search ((“Depression” OR “Depressive Disorder” OR “Postpartum Depression” OR “Major Depressive Disorder” OR “Dysthymic Disorder“
OR “dysthymia” OR “Seasonal Affective Disorder”))
2 Search ((“Depression”[Mesh] OR “Depressive Disorder”[Mesh] OR “Depression, Postpartum”[Mesh] OR “Depressive Disorder,
Major”[Mesh] OR “Dysthymic Disorder”[Mesh] OR “Seasonal Affective Disorder”[Mesh]))
3 Search (#1 or #2)
4 Search (#1 or #2) Filters: Publication date from 2014/10/01
5 Search (#1 or #2) Filters: Publication date from 2014/10/01; English
6 Search (#1 or #2) Filters: Publication date from 2014/10/01; English; Child: birth-18 years
7 Search ((#6 AND systematic[SB]))
8 Search ((depression[TIAB] OR depressed[TIAB] OR depressive[TIAB]))
9 Search ((child[TIAB] OR children[TIAB] OR adolescen*[TIAB] OR teen[TIAB] OR teens[TIAB] OR teenage*[TIAB]))
10 Search (#8 AND #9)
11 Search ((#10 AND (publisher[SB] OR in process[SB]))
12 Search ((#11 AND systematic[SB]))
13 Search ((#11 AND (meta-analysis[TIAB] OR medline[TIAB] OR systematic*[TIAB] OR search*[TIAB])))
14 Search (#12 or #13)
15 Search (#12 or #13) Filters: Publication date from 2014/10/01
16 Search (#12 or #13) Filters: Publication date from 2014/10/01; English
17 Search (#7 or #16)
18 Search (((#17) AND (“retraction”[All Fields] OR “Retracted Publication”[pt] OR Comment[pt] OR “Published Erratum”[pt] OR “Duplicate
Publication”[pt])))
19 Search ((((#17) AND (“retraction”[All Fields] OR “Retracted Publication”[pt] OR Comment[pt] OR “Published Erratum”[pt] OR “Duplicate
Publication”[pt])) Schema: all))
20 Search ((Mass Screening[MeSH] OR screen[TIAB] OR screening[TIAB] OR screened[TIAB] OR screens[TIAB] OR “case finding”[TIAB] OR
casefinding[TIAB] OR “depression inventory”[TIAB] OR “depression inventories”[TIAB] OR “depression scale”[TIAB] OR “depression
scales”[TIAB] OR “depression rating scale”[TIAB] OR “depression rating scales”[TIAB] OR “self report rating scale”[TIAB] OR “self report
rating scales”[TIAB] OR “mood and feelings questionnaire”[TIAB] OR “mood and feelings questionnaires”[TIAB] OR reynold*[TIAB] OR
kutcher*[TIAB] OR “depression scale for children”[TIAB] OR “beck depression inventory”[TIAB] OR “beck depression inventories”[TIAB]
OR “Center for Epidemiologic Studies Depression Scale”[TIAB] OR “Center for Epidemiologic Studies Depression Scales”[TIAB]))
21 Search ((Antidepressive Agents, Second-Generation[MeSH] OR Serotonin Uptake Inhibitors[MeSH] OR Antidepressive Agents[MeSH] OR
antidepressant*[TIAB] OR antidepressives[TIAB] OR (antidepressive agent*[TIAB]) OR (antidepressive drug*[TIAB]) OR (selective
serotonin reuptake inhibitor*[TIAB]) OR ssri[TIAB] OR ssris[TIAB] OR Fluoxetine[MeSH] OR fluoxetine[TIAB] OR Prozac[TIAB] OR
Fluvoxamine[MeSH] OR fluvoxamine[TIAB] OR luvox[TIAB] OR Paroxetine[MeSH] OR paroxetine[TIAB] OR paxil[TIAB] OR
Sertraline[MeSH] OR sertraline[TIAB] OR Zoloft[TIAB] OR Citalopram[MeSH] OR citalopram[TIAB] OR celexa[TIAB] OR escitalopram[TIAB]
OR Lexapro[TIAB]))
22 Search ((Psychotherapy[MeSH] OR Psychotherapy, Brief[MeSH] OR Psychotherapy, Group[MeSH] OR psychotherapy*[TIAB] OR Cognitive
Therapy[MeSH] OR (cognitive[TIAB] AND (therap*[TIAB] OR treatment*[TIAB] OR intervention*[TIAB])) OR Behavior Therapy[MeSH] OR
(behavior*[TIAB] AND (therap*[TIAB] or treatment*[TIAB] or intervention*[TIAB])) OR (interpersonal therap*[TIAB]) OR (interpersonal
intervention*[TIAB]) OR Self-Help Groups[MeSH] OR (self help[TIAB]) OR Family Therapy[MeSH] OR (family support[TIAB]) OR
(parent*[TIAB] AND education[TIAB]) OR Parents/education[MeSH] OR Counseling[MeSH] OR Directive Counseling[MeSH] OR
counsel*[TIAB] OR Problem Solving[MeSH] OR (problem solving[TIAB]))
23 Search ((“serotonin norepinephrine reuptake inhibitors”[All Fields] OR snri*[All Fields] OR “norepinephrine reuptake inhibitors”[all fields]
OR venlafaxine[Supplementary Concept] OR venlafaxine[All Fields] OR duloxetine[Supplementary Concept] OR duloxetine[All Fields]
OR Bupropion[MeSH] OR Bupropion[All Fields]))
24 Search ((#17 AND (#20 OR #21 OR #22 OR #23)))
MeSH = Medical Subject Heading.
* Example shown is for the most recently conducted PubMed search (see report for full list of data sources). Prior queries used terms shown but
limited publication dates to 2007 or later (2011 or later for systematic reviews and meta-analyses).
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Appendix Table 2. Key Questions
1. Does screening for MDD among children and adolescents in the
primary care (or comparable) setting lead to improved health and
other related outcomes overall and among subgroups defined by age,
sex, race, or ethnicity?
2. Are depression-screening instruments for children and adolescents
accurate in identifying MDD in primary care settings overall and
among subgroups defined by age, sex, race, or ethnicity?
3. Does screening increase the proportion of children and adolescents
identified with MDD overall and among subgroups defined by age,
sex, race, or ethnicity?
4. What are the harms of screening children and adolescents for MDD
overall and among subgroups defined by age, sex, race, or ethnicity?
5. Does treatment of MDD among children and adolescents identified in
primary care improve health and other related outcomes overall and
among subgroups defined by age, sex, race, or ethnicity?
6. What are the harms of MDD treatment for children and adolescents
overall and among subgroups defined by age, sex, race, or ethnicity?
MDD = major depressive disorder.
Appendix Figure 1. Analytic framework for screening for childhood depression.
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Appendix Figure 2. Summary of evidence search and selection.
Records identified through database 
searching (n = 12 816)
   PubMed: 9762
   Cochrane: 1733
   PsychInfo: 1321
Additional records identified through other
sources (n = 975)
   ClinicalTrials.gov: 622
   HSRProj: 157
   WHO ICTRP: 195
   Hand search: 1
   Suggestions from public comments: 0
Duplicates removed (n = 3786)
Records screened (n = 10 005)
   PubMed: 6809
   Cochrane: 1017
   PsychInfo: 1274
   ClinicalTrials.gov: 563
   HSRProj: 149
   WHO ICTRP: 193
Records excluded (n = 9638)
Full-text articles assessed for eligibility (n = 367)
Full-text articles excluded (n = 361)
   Wrong publication type/not original 
      research: 36
   Wrong population: 171
   Wrong comparator: 51
   Wrong outcome: 29
   Wrong timing: 0
   Wrong setting: 7
   Wrong geographical setting: 0
   Wrong study design: 15
   Wrong intervention: 23
   Wrong sample size for cohort studies: 0
   Wrong publication dates: 12
   Wrong language/non-English: 6
   Included in 2009 evidence synthesis: 5
   Article irretrievable: 6
Studies from 6 articles met inclusion criteria
(n = 5)
   Poor-quality studies excluded from analysis:
      3 (in 4 articles)
   Fair- or good-quality studies included in 
      quantitative synthesis: 2
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Studies were published since May 2007. HSRProj = Health Services Research Projects in Progress; WHO ICTRP = World Health Organization
International Clinical Trials Registry Platform.
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